KK
Therapeutic Areas
PepGen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PGN-EDODM1 | Myotonic Dystrophy Type 1 (DM1) | Phase 2 |
| PGN-EDO51 | Duchenne Muscular Dystrophy (DMD) amenable to Exon 51 Skipping | Phase 2 |
Leadership Team at PepGen
JM
James McArthur
President and Chief Executive Officer
ND
Noel Donnelly
Chief Financial Officer
JV
Joseph Vittiglio
Chief Business and Legal Officer
PS
Paul Streck
Executive Vice President, Head of Research & Development
HP
Hayley Parker
Senior Vice President, Global Regulatory Affairs & Quality
EB
Emiko Bryant
Senior Vice President, HR and Administration
JL
Jane Larkindale
Vice President, Clinical Science
PL
Pallavi Lonkar
Vice President, Head of Preclinical
RL
Rod Lozano
Vice President, Information Technology
DS
Debra Sawyer
Vice President, Quality Assurance